SPPL2A Gene

SPPL2A Gene

Full Name: Signal Peptidase Like 2A (Intramembrane Aspartyl Protease) Chromosome: 15q21.3 NCBI Gene ID: 84888 OMIM ID: 607260 Ensembl ID: ENSG00000119774 UniProt ID: Q8TDS0

<div class="infobox infobox-gene">
<h3>SPPL2A</h3>
<table>
<tr><th>Full Name</th><td>Signal Peptidase Like 2A</td></tr>
<tr><th>Chromosome</th><td>15q21.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[84888](https://www.ncbi.nlm.nih.gov/gene/84888)</td></tr>
<tr><th>OMIM</th><td>[607260](https://www.omim.org/entry/607260)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000119774](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119774)</td></tr>
<tr><th>UniProt ID</th><td>[Q8TDS0](https://www.uniprot.org/uniprot/Q8TDS0)</td></tr>
<tr><th>Protein Class</th><td>Intramembrane aspartyl protease</td></tr>
<tr><th>Protein Size</th><td>617 amino acids (~69 kDa)</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Immune Disorders</td></tr>
<tr><th>Expression</th><td>Ubiquitous: Brain, immune cells, kidney, liver</td></tr>
</table>
</div>

Introduction

SPPL2A Gene

Full Name: Signal Peptidase Like 2A (Intramembrane Aspartyl Protease) Chromosome: 15q21.3 NCBI Gene ID: 84888 OMIM ID: 607260 Ensembl ID: ENSG00000119774 UniProt ID: Q8TDS0

<div class="infobox infobox-gene">
<h3>SPPL2A</h3>
<table>
<tr><th>Full Name</th><td>Signal Peptidase Like 2A</td></tr>
<tr><th>Chromosome</th><td>15q21.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[84888](https://www.ncbi.nlm.nih.gov/gene/84888)</td></tr>
<tr><th>OMIM</th><td>[607260](https://www.omim.org/entry/607260)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000119774](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119774)</td></tr>
<tr><th>UniProt ID</th><td>[Q8TDS0](https://www.uniprot.org/uniprot/Q8TDS0)</td></tr>
<tr><th>Protein Class</th><td>Intramembrane aspartyl protease</td></tr>
<tr><th>Protein Size</th><td>617 amino acids (~69 kDa)</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Immune Disorders</td></tr>
<tr><th>Expression</th><td>Ubiquitous: Brain, immune cells, kidney, liver</td></tr>
</table>
</div>

Introduction

SPPL2A (Signal Peptidase Like 2A) encodes an intramembrane aspartyl protease that catalyzes the proteolytic cleavage of type II membrane proteins within their transmembrane domains. This enzyme, also known as intramembrane-cleaving aspartic protease (I-CLiP), plays crucial roles in immune signaling, amyloid precursor protein (APP) processing, and has been increasingly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.

The discovery of SPPL2A expanded our understanding of regulated intramembrane proteolysis (RIP) as a fundamental cellular signaling mechanism. Unlike classical proteases that cleave substrates in aqueous environments, SPPL2A operates within the lipid bilayer, making it unique among enzymatic proteins involved in cellular signaling. This mechanism allows cells to generate bioactive fragments from membrane-bound precursors, enabling rapid responses to various stimuli.

The enzyme belongs to the signal peptide peptidase (SPP) family, which is evolutionarily conserved from bacteria to humans. SPPL2A shares structural features with other intramembrane proteases including presenilins (the catalytic component of gamma-secretase), but differs in substrate specificity and biological functions. The importance of SPPL2A in cellular homeostasis is underscored by the fact that knockout mice exhibit profound immune deficiencies, highlighting its essential role in immune system development and function.

Molecular Function

SPPL2A is a member of the signal peptide peptidase (SPP) family of intramembrane proteases. Unlike traditional proteases that cleave substrates in aqueous environments, SPPL2A cleaves substrates within the lipid bilayer, making it unique among enzymatic proteins. This process, known as regulated intramembrane proteolysis (RIP), generates bioactive fragments that can function as signaling molecules or be further degraded.

Catalytic Mechanism

SPPL2A contains the characteristic aspartyl protease motifs within its transmembrane domains:

• Active site residues: Conserved Asp-Thr-Ser-Leu (DTSL) motif in transmembrane domain VI
• Y/D motif: Conserved tyrosine-aspartate pair in transmembrane domain VII
• LGL motif: Leucine-glycine-leucine sequence involved in substrate recognition
• The active site resides within the membrane, allowing cleavage of membrane-bound substrates
• Requires dimerization for catalytic activity, forming functional homodimers

Substrate Specificity

SPPL2A processes multiple physiologically important substrates, making it a biologically significant enzyme in multiple pathways [@martinelli2020][@vonesh2016]:

Protein Structure

The SPPL2A protein features several distinct domains:

• N-terminal region: Contains a PDZ domain for protein-protein interactions
• Proline-rich region: Mediates interactions with SH3 domain-containing proteins
• Transmembrane domains: 9-10 transmembrane helices spanning the membrane
• C-terminal domain: Contains the catalytic aspartyl protease motifs

Disease Associations

Alzheimer's Disease

SPPL2A plays a complex role in APP processing. Unlike beta-secretase (BACE1) which generates [amyloid-beta](/proteins/amyloid-beta) peptides, SPPL2A cleaves APP at a different site, potentially generating non-amyloidogenic fragments. This alternative processing pathway has generated significant interest in SPPL2A as a potential therapeutic target for reducing amyloid-beta production [@mentrup2019][@schmidt2018].

The relationship between SPPL2A and AD involves several mechanisms:

• Non-amyloidogenic processing: SPPL2A cleavage of APP can prevent Aβ generation
• Alpha-cleavage: Produces soluble APP-alpha (sAPPα) with neuroprotective properties
• Interaction with gamma-secretase: Coordinate processing of APP by multiple proteases
• Therapeutic targeting: Modulating SPPL2A activity could shift APP processing away from amyloidogenic pathways

Parkinson's Disease

SPPL2A is highly expressed in dopaminergic [neurons](/entities/neurons) of the substantia nigra, the brain region most affected in Parkinson's disease. Studies have revealed multiple connections between SPPL2A and PD pathogenesis [@zhang2021][@yang2018][@liao2022]:

Immune-Related Neuroinflammation

Given its role in processing TNF-alpha and Fas ligand, SPPL2A contributes significantly to neuroinflammatory processes relevant to multiple neurodegenerative diseases [@martinelli2020][@baranger2016][@pan2020]:

• TNF-alpha processing: Generates soluble TNF-alpha that activates inflammatory signaling
• FasL cleavage: Regulates apoptosis in immune cells and neurons
• Cytokine regulation: Modulates neuroinflammatory responses through multiple cytokine pathways
• Microglial activation: Affects microglial function and inflammatory phenotype

Expression Pattern

SPPL2A is ubiquitously expressed with high levels in:

• Brain (cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), substantia nigra, cerebellum)
• Immune cells (T cells, B cells, macrophages, dendritic cells)
• Peripheral tissues (kidney, liver, pancreas, lung)
• Cell types: neurons, microglia, astrocytes, oligodendrocytes

Brain Region-Specific Expression

Within the brain, SPPL2A shows region-specific distribution:

• Cerebral cortex: High expression in pyramidal neurons
• Hippocampus: Particularly abundant in CA1-CA3 regions
• Substantia nigra: High levels in dopaminergic neurons
• Cerebellum: Expression in Purkinje cells and granule cells
• Microglia: Constitutive expression in resident immune cells

Therapeutic Implications

SPPL2A has emerged as a potential therapeutic target for neurodegenerative diseases. However, its broad substrate specificity and essential roles in immune function present challenges for selective targeting.

Therapeutic Strategies

Challenges

• Broad substrate specificity: SPPL2A processes many substrates, making selective targeting difficult
• Immune system effects: Essential functions in immune cells complicate systemic delivery
• Blood-brain barrier: Delivery to the CNS remains a significant challenge

Preclinical and Clinical Status

• Small molecule inhibitors have been developed but lack CNS penetration
• Antibody-based approaches are being explored for immune applications
• No clinical trials for neurodegenerative diseases as of 2024

Key Publications

References

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease associated with SPPL2A
• [Parkinson's Disease](/diseases/parkinsons-disease) — Neurodegenerative movement disorder
• [Amyloid Precursor Protein](/entities/app-protein) — APP processing pathways
• [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory mechanisms
• [Intramembrane Proteolysis](/mechanisms/proteolysis-intramembrane) — Proteolytic processing
• [Beta-Secretase](/entities/bace1) — Alternative APP processing enzyme

External Links

• [NCBI Gene: SPPL2A](https://www.ncbi.nlm.nih.gov/gene/84888)
• [UniProt: SPPL2A](https://www.uniprot.org/uniprot/Q8TDS0)
• [Ensembl: SPPL2A](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119774)
• [OMIM: 607260](https://www.omim.org/entry/607260)